Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
10.21
+0.04 (0.39%)
At close: Jan 22, 2025, 4:00 PM
10.37
+0.16 (1.57%)
After-hours: Jan 22, 2025, 4:32 PM EST
Immunome Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immunome stock have an average target of 28.6, with a low estimate of 21 and a high estimate of 35. The average target predicts an increase of 180.12% from the current stock price of 10.21.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for Immunome stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $21 | Buy | Maintains | $23 → $21 | +105.68% | Nov 14, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $30 | Buy | Initiates | $30 | +193.83% | Nov 8, 2024 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +223.21% | Oct 25, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $27 → $23 | Buy | Maintains | $27 → $23 | +125.27% | Aug 13, 2024 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +223.21% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
9.60M
from 14.02M
Decreased by -31.50%
Revenue Next Year
3.16M
from 9.60M
Decreased by -67.09%
EPS This Year
-4.47
from -5.38
EPS Next Year
-3.06
from -4.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 16.8M | 9.5M | 50.4M | |||
| Avg | 9.6M | 3.2M | 18.2M | |||
| Low | 6.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 19.8% | -1.6% | 1,494.9% | |||
| Avg | -31.5% | -67.1% | 476.8% | |||
| Low | -56.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.21 | -2.37 | -1.99 | |||
| Avg | -4.47 | -3.06 | -3.05 | |||
| Low | -4.54 | -4.09 | -4.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.